Özel Hasta Gruplarında Pulmoner Hipertansiyon
Özet
Pulmoner hipertansiyon (PH), gebelik, ileri yaş ve çocukluk döneminde farklı klinik özellikler gösteren, yüksek morbidite ve mortalite ile ilişkili bir hastalık grubudur. Gebelikte, özellikle pulmoner arteriyel hipertansiyon (PAH) olgularında maternal ölüm riski yüksektir ve gebelik genellikle kontrendikedir. Gebeliğin sürdürüldüğü durumlarda multidisipliner yaklaşım, hedefe yönelik tedaviler ve planlı doğum stratejileri sonuçları iyileştirebilmektedir. Yaşlı hastalarda PH sıklığı artmakta; sol kalp hastalıkları, komorbiditeler ve polifarmasi tanı ve tedaviyi güçleştirmektedir. Pediatrik PH ise genetik yatkınlık, konjenital kalp hastalıkları ve gelişimsel akciğer hastalıkları ile yakın ilişkilidir. Erken tanı ve uygun tedavi sağkalımı artırsa da prognoz önemli bir klinik sorun olmaya devam etmektedir. PH’nin tüm yaş gruplarında bireyselleştirilmiş ve multidisipliner yönetimi gereklidir.
Pulmonary hypertension (PH) is a disease group associated with high morbidity and mortality, exhibiting distinct clinical characteristics during pregnancy, advanced age, and childhood. In pregnancy, particularly in pulmonary arterial hypertension (PAH), maternal mortality risk is high and pregnancy is generally contraindicated. When pregnancy continues, multidisciplinary care, targeted therapies, and planned delivery strategies may improve outcomes. In elderly patients, PH is increasingly prevalent and often accompanied by left heart disease, comorbidities, and polypharmacy, complicating diagnosis and management. Pediatric PH is strongly associated with genetic predisposition, congenital heart disease, and developmental lung disorders. Although early diagnosis and appropriate treatment have improved survival, prognosis remains a significant concern. Individualized and multidisciplinary management is essential for optimizing outcomes across all age groups.
Referanslar
Humbert M, Kovacs G, Hoeper MM, Badagliacca R, Berger RMF, Brida M, et al. 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Respir J. 2023 Jan;61(1):2200879. doi:10.1183/13993003.00879-2022
Jaïs X, Olsson KM, Barbera JA, Blanco I, Torbicki A, Peacock A, et al. Pregnancy outcomes in pulmonary arterial hypertension in the modern management era. Eur Respir J. 2012 Oct;40(4):881–5. doi:10.1183/09031936.00141211
Hemnes AR, Kiely DG, Cockrill BA, Safdar Z, Wilson VJ, Hazmi M Al, et al. Statement on Pregnancy in Pulmonary Hypertension from the Pulmonary Vascular Research Institute. Pulm Circ. 2015 Sep;5(3):435–65. doi:10.1086/682230
Olsson KM, Channick R. Pregnancy in pulmonary arterial hypertension. Eur Respir Rev. 2016 Dec;25(142):431–7. doi:10.1183/16000617.0079-2016
Regitz-Zagrosek V, Roos-Hesselink JW, Bauersachs J, Blömstrom-Lundqvist C, Cífková R, De Bonis M, et al. 2018 ESC Guidelines for the management of cardiovascular diseases during pregnancy. Eur Heart J. 2018 Sep 7;39(34):3165–241. doi:10.1093/eurheartj/ehy340
Curry R, Fletcher C, Gelson E, Gatzoulis M, Woolnough M, Richards N, et al. Pulmonary hypertension and pregnancy—a review of 12 pregnancies in nine women. BJOG. 2012 May 6;119(6):752–61. doi:10.1111/j.1471-0528.2012.03295.x
Bedard E, Dimopoulos K, Gatzoulis MA. Has there been any progress made on pregnancy outcomes among women with pulmonary arterial hypertension? Eur Heart J. 2008 Sep 10;30(3):256–65. doi:10.1093/eurheartj/ehn597
Kiely D, Condliffe R, Webster V, Mills G, Wrench I, Gandhi S, et al. Improved survival in pregnancy and pulmonary hypertension using a multiprofessional approach. BJOG. 2010 Apr 10;117(5):565–74. doi:10.1111/j.1471-0528.2009.02492.x
Olsson K, Jais X. Birth Control and Pregnancy Management in Pulmonary Hypertension. Semin Respir Crit Care Med. 2013 Sep 13;34(05):681–8. doi:10.1055/s-0033-1355438
Sliwa K, van Hagen IM, Budts W, Swan L, Sinagra G, Caruana M, et al. Pulmonary Hypertension and Pregnancy Outcomes: Data from the Registry Of Pregnancy and Cardiac Disease (ROPAC) of the European Society of Cardiology. Eur J Heart Fail. 2016 Sep 1;18(9):1119–28. doi:10.1002/ejhf.594
Hoeper MM, Huscher D, Ghofrani HA, Delcroix M, Distler O, Schweiger C, et al. Elderly patients diagnosed with idiopathic pulmonary arterial hypertension: Results from the COMPERA registry. Int J Cardiol. 2013 Sep;168(2):871–80. doi:10.1016/j.ijcard.2012.10.026
Hjalmarsson C, Rådegran G, Kylhammar D, Rundqvist B, Multing J, Nisell MD, et al. Impact of age and comorbidity on risk stratification in idiopathic pulmonary arterial hypertension. Eur Respir J. 2018 May;51(5):1702310. doi:10.1183/13993003.02310-2017
Rosenkranz S, Pausch C, Coghlan JG, Huscher D, Pittrow D, Grünig E, et al. Risk stratification and response to therapy in patients with pulmonary arterial hypertension and comorbidities: A COMPERA analysis. J Heart Lung Transplant. 2023 Jan;42(1):102–14. doi:10.1016/j.healun.2022.10.003
Ahmed A, Ahmed S, Rådegran G. Risk assessment in pulmonary arterial hypertension patients with multiple comorbidities and/or advanced age—Where do we stand and what’s next? Pulm Circ. 2023 Oct 30;13(4). doi:10.1002/pul2.12314
Norell PN, Ivarsson B, Selin M, Kjellström B. Prevalence of potential drug–drug interactions with disease‐specific treatments in patients with pulmonary arterial hypertension or chronic thromboembolic pulmonary hypertension: A registry study. Pulm Circ. 2022 Jul 22;12(3). doi:10.1002/pul2.12114
Wu S, Hoang HB, Yang JZ, Papamatheakis DG, Poch DS, Alotaibi M, et al. Drug-Drug Interactions in the Management of Patients With Pulmonary Arterial Hypertension. Chest. 2022 Dec;162(6):1360–72. doi:10.1016/j.chest.2022.06.042
Grünig E, Eichstaedt C, Barberà JA, Benjamin N, Blanco I, Bossone E, et al. ERS statement on exercise training and rehabilitation in patients with severe chronic pulmonary hypertension. Eur Respir J. 2019 Feb;53(2):1800332. doi:10.1183/13993003.00332-2018
Rosenzweig EB, Abman SH, Adatia I, Beghetti M, Bonnet D, Haworth S, et al. Paediatric pulmonary arterial hypertension: updates on definition, classification, diagnostics and management. Eur Respir J. 2019 Jan;53(1):1801916. doi:10.1183/13993003.01916-2018
Berger RM, Beghetti M, Humpl T, Raskob GE, Ivy DD, Jing ZC, et al. Clinical features of paediatric pulmonary hypertension: a registry study. Lancet. 2012 Feb;379(9815):537–46. doi:10.1016/S0140-6736(11)61621-8
van Loon RLE, Roofthooft MTR, Hillege HL, ten Harkel ADJ, van Osch-Gevers M, Delhaas T, et al. Pediatric Pulmonary Hypertension in the Netherlands. Circulation. 2011 Oct 18;124(16):1755–64. doi:10.1161/CIRCULATIONAHA.110.969584
Ivy DD, Abman SH, Barst RJ, Berger RMF, Bonnet D, Fleming TR, et al. Pediatric Pulmonary Hypertension. J Am Coll Cardiol. 2013 Dec;62(25):D117–26. doi:10.1016/j.jacc.2013.10.028
Abman SH, Hansmann G, Archer SL, Ivy DD, Adatia I, Chung WK, et al. Pediatric Pulmonary Hypertension. Circulation. 2015 Nov 24;132(21):2037–99. doi:10.1161/CIR.0000000000000329
Hansmann G, Koestenberger M, Alastalo TP, Apitz C, Austin ED, Bonnet D, et al. 2019 updated consensus statement on the diagnosis and treatment of pediatric pulmonary hypertension: The European Pediatric Pulmonary Vascular Disease Network (EPPVDN), endorsed by AEPC, ESPR and ISHLT. J Heart Lung Transplant. 2019 Sep;38(9):879–901. doi:10.1016/j.healun.2019.06.022
Beghetti M, Berger RMF, Schulze-Neick I, Day RW, Pulido T, Feinstein J, et al. Diagnostic evaluation of paediatric pulmonary hypertension in current clinical practice. Eur Respir J. 2013 Sep;42(3):689–700. doi:10.1183/09031936.00140112
Lammers AE, Apitz C, Zartner P, Hager A, Dubowy KO, Hansmann G. Diagnostics, monitoring and outpatient care in children with suspected pulmonary hypertension/paediatric pulmonary hypertensive vascular disease. Expert consensus statement on the diagnosis and treatment of paediatric pulmonary hypertension. The European Paediatric Pulmonary Vascular Disease Network, endorsed by ISHLT and DGPK. Heart. 2016 May;102(Suppl 2):ii1–13. doi:10.1136/heartjnl-2015-307792
Ploegstra MJ, Ivy DD, Beghetti M, Bonnet D, Alehan D, Ablonczy L, et al. Long-term outcome of children with newly diagnosed pulmonary arterial hypertension: results from the global TOPP registry. Eur Heart J Qual Care Clin Outcomes. 2024 Jan 12;10(1):66–76. doi:10.1093/ehjqcco/qcad020
